Cemiplimab concentrations in serum in patients from the cemiplimab plus chemotherapy arm were similar, irrespective of tumor histology type and baseline PD-L1 expression level, and in agreement with those reported for cemiplimab monotherapy. Here, CD274 is linked to neoplasm.